Back to top

Lilly Advances MASLD Pipeline as Early-Stage LY3849891 Study Reaches Completion

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The phase 1 study “A Single-Ascending and Repeated Subcutaneous D...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Eli Lilly and Company (LLY)